ClinicalTrials.gg
Active, not recruitingNCT07286474LLLTUpdated Apr 28, 2026

Effects of Laser Therapy and Vitamin D Pills on Braces Tooth Movement: A Random Controlled Study

An interventional study of Cholecalciferol (Vit D3) and Low-Level Laser Therapy in Malocclusion of Anterior Teeth, sponsored by Universiti Sains Malaysia. Active, not recruiting at 1 site in Saudi Arabia. Open to participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-28.

Sponsored by Universiti Sains Malaysia · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
All
01

Study summary

This clinical trial aims to evaluate the efficacy of low-level laser therapy (LLLT) in conjunction with oral vitamin D3 supplementation in accelerating orthodontic tooth movement in adults with crowded mandibular anterior teeth undergoing orthodontic treatment. Additionally, the study seeks to assess the safety profile and potential adverse effects, including pain and root resorption.

The primary research questions are as follows:

  1. Does vitamin D3 enhance the rate of orthodontic tooth movement?
  2. Does the combination of vitamin D3 and LLLT result in a greater acceleration of tooth movement compared to either intervention alone?
  3. Do vitamin D3 and LLLT influence the extent of root resorption?
  4. Do vitamin D3 and LLLT mitigate pain associated with orthodontic treatment?
  5. Do vitamin D3 and LLLT reduce the frequency of required clinical visits?

The study will compare the outcomes of orthodontic treatment with braces alone, braces with vitamin D3 supplementation, and braces with both vitamin D3 and LLLT, to determine their effects on the rate of tooth movement, pain reduction, and root resorption.

Participants will undergo the following procedures:

  • A blood test to assess baseline vitamin D levels.
  • Placement of orthodontic braces.
  • Daily administration of vitamin D3 supplements for those assigned to the relevant groups, commencing with a loading dose one week prior to the initiation of orthodontic treatment.
  • Application of LLLT to the gingival tissues for participants in the corresponding group, administered at the start and during follow-up visits.
  • Regular clinic visits every four weeks for monitoring, pain assessment, and measurement of tooth movement until the completion of orthodontic alignment.
Read the detailed description

Orthodontic treatment is instrumental in aligning teeth and enhancing both aesthetic and functional aspects of smiles and bites. However, the duration of such treatment is typically protracted, averaging between 1.5 to 3 years. This extended timeframe can result in complications such as discomfort, root resorption, plaque accumulation, periodontal issues, and enamel demineralization. Both patients undergoing orthodontic treatment and their orthodontists seek methods to expedite the process without compromising safety. Orthodontic tooth movement is facilitated by the application of gentle forces through Standard Orthodontic treatment , which induce remodeling of the surrounding bone. This process involves bone resorption on one side and new bone formation on the other, mediated by osteoclasts and osteoblasts, as well as the involvement of blood vessels and nerves within the periodontal tissues. Over time, various strategies have been explored to accelerate tooth movement. Surgical interventions, such as corticotomy or piezocision, have demonstrated efficacy in hastening the process but are invasive and may cause apprehension among patients. Non-surgical approaches, including vibrational devices, magnetic fields, or hormonal injections, have been investigated, though some present adverse effects or limited efficacy. Low-level laser therapy (LLLT) emerges as a non-invasive alternative, utilizing low-energy light to enhance healing processes. LLLT has been shown to augment blood circulation, reduce inflammation, and enhance the function of bone cells. Empirical evidence suggests that LLLT may accelerate orthodontic tooth movement by modulating proteins and cellular activities involved in bone remodeling, such as increasing RANKL expression, which facilitates bone resorption, and alleviating orthodontic pain.

Vitamin D3, commonly referred to as the "sunshine vitamin," is essential for maintaining bone health. It is synthesized in the body through skin exposure to sunlight or obtained from dietary sources such as fish, eggs, or supplements. Vitamin D3 plays a crucial role in regulating calcium and phosphorus levels, which are vital for strong bones. In the field of orthodontics, vitamin D3 may facilitate bone remodeling during tooth movement. Animal studies have indicated that local injections of vitamin D3 near teeth can enhance movement; however, human studies have yielded mixed results, with some demonstrating accelerated movement with local vitamin D3 application, while others do not. Oral supplementation is considered safer and more convenient, yet there is a paucity of research examining its effects on orthodontic treatment. To date, no studies have investigated the combined use of low-level laser therapy (LLLT) and oral vitamin D3. It is hypothesized that these interventions may have a synergistic effect: vitamin D3 enhances bone metabolism, while LLLT reduces inflammation and promotes healing. This study aims to address this gap by evaluating whether the combination of LLLT and oral vitamin D3 accelerates the alignment of crowded lower anterior teeth more effectively than either treatment alone, while also monitoring potential side effects such as pain or root resorption.

This study is a randomized controlled trial comprising three groups to facilitate an equitable comparison of treatments. The participants are adults aged 18 to 40 years, exhibiting moderate dental crowding (4-8 mm) in the mandibular anterior region, necessitating orthodontic intervention. Eligibility criteria include normal vitamin D levels, overall good health, and a complete set of permanent teeth. Exclusion criteria encompass individuals with deficient vitamin D levels, specific medical conditions (such as thyroid or renal disorders), pregnancy, or inadequate oral hygiene. The target sample size is approximately 39 participants, distributed equally among the groups: Group A will receive orthodontic Standard Orthodontic treatment in conjunction with daily vitamin D3 supplementation, beginning with a high dose followed by maintenance dosing; Group B will receive Standard Orthodontic treatment , vitamin D3 supplementation, and low-level laser therapy (LLLT); the Control Group will receive Standard Orthodontic treatment only. Randomization is conducted using software to mitigate bias. The study adheres to ethical standards and the CONSORT guidelines to ensure transparent reporting.Procedures Initially, all participants undergo blood tests to assess vitamin D levels. Individuals with deficient levels are referred for treatment and are excluded from participation. Eligible participants provide informed consent and undergo standard orthodontic documentation, including photographs, X-rays, and study models. The orthodontic treatment commences with the application of 0.022" MBT-type Standard Orthodontic treatment on both the upper and lower dentition. The orthodontic wires are incrementally thickened to facilitate dental alignment, beginning with 0.014" flexible nickel-titanium, followed by 0.016", 0.016x0.022", and ultimately 0.017x0.025" steel wires. For the vitamin D3 cohort, a 50,000 IU dose is administered one week prior to the initiation of orthodontic treatment, followed by a daily intake of 1,000 IU until dental alignment is achieved. In the Low-Level Laser Therapy (LLLT) group, a diode laser (940 nm, 2.5 W power) equipped with a whitening handpiece is employed. The laser light is applied directly to the gingival tissue above the lower anterior teeth for 30 seconds at the commencement of treatment, on day 14, day 30, and subsequently every four weeks. Protective eyewear is mandatory during these sessions. Progress evaluations occur at four-week intervals, utilizing Little's Irregularity Index on study models to quantify dental crowding by summing the interproximal contact point discrepancies of the lower anterior teeth. Treatment concludes when the index reaches 0 mm, indicating complete alignment. Root resorption is assessed through comparative pre- and post-treatment X-rays of the lower anterior teeth, graded on a scale from 0 (no change) to 4 (severe resorption). Pain levels are documented daily for seven days following each wire adjustment or laser session, using a 10-cm visual analog scale (0 indicating no pain, 10 indicating the most severe pain). Participants also record any analgesic consumption. Data analysis involves statistical tests to compare the groups regarding treatment duration, root resorption, and pain levels. The findings have the potential to inform the development of more efficient and less painful orthodontic treatment protocols.

02

Conditions studied

  • Malocclusion of Anterior Teeth

Browse trials for

Keywords

  • LLLT, vitamin D3 supplements, randomized controlled trial, mandibular crowding, root resorption, pain perception, acceleration of orthodontics
03

In context

Root Resorption

43 studies on the registry are indexed under Root Resorption; 9 are open to participants now.

This study's planned enrollment of 50 is above the median of 29 across 36 interventional studies indexed under Root Resorption.

Browse Root Resorption studies →

Lead sponsor

Universiti Sains Malaysia is the lead sponsor of 177 studies on the registry; 51 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants requiring orthodontic treatment for crowding in the range of 4 to 8 mm in the lower anterior segment.

  • Age range: 18 to 40 years.
  • Angles Class I, II or III malocclusion
  • Fully erupted permanent dentition
  • Good oral and general health

- Normal range of Vitamin D levels

Exclusion criteria

Exclusion Criteria:

  • Deficiency of Vitamin D levels below normal range. • Medically compromised patients with thyroid, parathyroid, or renal and liver diseases.

Patients on medication, especially and anticonvulsant drugs • Poor oral hygiene

  • Pregnancy
  • Lactation
  • History of craniofacial abnormalities or syndromes that may affect orthodontic tooth movements.
  • Participants failing to complete the Vitamin D supplementation log sheets will be excluded to ensure accurate data collection.
  • Inability to comply with the study protocol or unable to complete the study due to personal, medical, or logistical reasons (e.g., missed follow-up visits or failure to undergo assessments) will be excluded to maintain data integrity and minimize biases from incomplete participation.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Vitamin D3 Only Group

    Participants receive standard orthodontic treatment with pre-adjusted edgewise brackets (0.022" MBT prescription) and wire sequencing (0.014" NiTi initial, progressing to 0.017x0.025" SS). Additionally, oral Vitamin D3 supplementation: single loading dose of 50,000 IU one week before treatment, followed by 1,000 IU daily maintenance until alignment completion. No LLLT.

    Dietary Supplement: Cholecalciferol (Vit D3) · Device: Fixed Orthodontic Appliance

  • Experimental
    Vitamin D3 + LLLT Group

    Participants receive standard orthodontic treatment as above. Plus oral Vitamin D3 supplementation (50,000 IU loading one week before, 1,000 IU daily). Plus LLLT using InGaAlAs diode laser (940 nm, 2.5 W, 25.7 J/cm², 30 seconds labially at muco-gingival junction) initiated at alignment start, repeated on days 14 and 30, then every 4 weeks until completion.

    Dietary Supplement: Cholecalciferol (Vit D3) · Radiation: Low-Level Laser Therapy

  • Active comparator
    Control Group

    Participants receive only standard orthodontic treatment with pre-adjusted edgewise brackets (0.022" MBT prescription) and wire sequencing (0.014" NiTi initial, progressing to 0.017x0.025" SS). No Vitamin D3 supplementation or LLLT.

    Device: Fixed Orthodontic Appliance

Interventions

  • Dietary supplementCholecalciferol (Vit D3)

    Oral cholecalciferol supplementation: initial loading dose of 50,000 IU one week before orthodontic treatment initiation, followed by daily maintenance dose of 1,000 IU until alignment completion. Administered to participants with baseline sufficient Vitamin D levels.

  • RadiationLow-Level Laser Therapy

    Diode laser (Biolase 10W 940±10nm, InGaAlAs) with tooth whitening handpiece (spot size 2.8 cm²), wavelength 940 nm, power output 2.5 W, energy density 25.7 J/cm², continuous wave mode. Applied labially in direct contact at mucogingival junction for 30 seconds. Initiated at alignment start, repeated on days 14 and 30, then every 4 weeks until completion. Eye protection worn by operator and participant.

  • DeviceFixed Orthodontic Appliance

    Pre-adjusted edgewise conventional brackets with 0.022" MBT (McLaughlin Bennett Trevisi) prescription (3M Unitek), bondable 0.022" single slot molar tubes, bonded using Transbond XT light cure material on upper and lower arches. Wire sequencing: initial 0.014" super elastic nickel-titanium (SE-NiTi), followed by 0.016" SE-NiTi, 0.016 x 0.022" SE-NiTi, and finally 0.017 x 0.025" stainless steel wire until alignment completion. Adjustments every 4 weeks.

06

What researchers measure

Primary outcomes

  1. Rate of Orthodontic Tooth Movement

    The rate of reduction in mandibular anterior crowding, measured in mm/month using Little's Irregularity Index (sum of linear displacements between contact points of the six mandibular anterior teeth from canine to canine, assessed via dental models). Compared across groups to evaluate acceleration effects.

    Time frame: From baseline (initiation of alignment) to complete alignment (Little's Irregularity Index reaches 0 mm), assessed every 4 weeks (estimated duration 6-10 months per participant)

Secondary outcomes

  1. Root Resorption

    Degree of apical root resorption in mandibular anterior teeth, assessed using periapical radiographs and graded on a 0-4 scale (0 = no resorption, 4 = severe resorption \>4 mm). Compared between baseline and post-alignment images.

    Time frame: Baseline and at completion of alignment (estimated 6-10 months)

  2. Pain Perception

    Orthodontic pain intensity measured using a 10-cm Visual Analogue Scale (VAS; 0 = no pain, 10 = worst pain imaginable). Participants record daily scores for 7 days following each archwire activation or LLLT session.

    Time frame: Daily for 7 days after each monthly visit, throughout the alignment phase (up to 10 months)

  3. Duration of Orthodontic Alignment

    Total time required to achieve complete resolution of mandibular anterior crowding (from initiation of fixed appliance treatment to Little's Irregularity Index of 0 mm).

    Time frame: From baseline to complete alignment, monitored every 4 weeks (estimated 6-10 months)

07

Study locations

1 site
  • Armed Forces Hospital
    Madinah, Madinah 42314, Saudi Arabia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Oct 2026, 9 months after the start.

Of 25 interventional studies with no phase under Root Resorption, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 41. This study's planned 9 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 2, 2025
First posted
Dec 16, 2025
StartActual
Jan 1, 2026
Primary completionEst.
Oct 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Apr 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07286474
Responsible party
Syed Abid Altaf Bukhari (PhD Student, Universiti Sains Malaysia) — Principal investigator
First posted
Dec 16, 2025
Start date
Jan 1, 2026
Primary completion
Oct 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Apr 28, 2026

Study contacts

Rozita Hassan, BDS, MS, MOrtho RCSEd
study director · Universiti Sains Malayisa

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cholecalciferol

Start the discussion